Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 9/20 | 0.65 |
| ▸ | VCP | P55072 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CFTR | P13569 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.55 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208192 | 0.89 | ALOX5 (0.72) | ALOX5VCPMAPTTDP1NPC1 | |
| SCHEMBL205976 | 0.89 | ALOX5 (0.80) | ALOX5VCPMAPTSMN1; SMN2TDP1 | |
| SCHEMBL7113187 | 0.87 | ALOX5 (0.65) | ALOX5VCPMAPTTDP1RAB9A | |
| SCHEMBL6156291 | 0.86 | MEN1 (0.66) | ALOX5VCPMAPTSMN1; SMN2RAB9A | |
| SCHEMBL26126062 | 0.86 | ALOX5 (0.85) | ALOX5VCPMAPTSMN1; SMN2TDP1 | |
| SCHEMBL206675 | 0.86 | ALOX5 (0.58) | ALOX5VCPMAPTSMN1; SMN2TDP1 | |
| SCHEMBL4958876 | 0.86 | MEN1 (0.69) | ALOX5VCPMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1885333 | 0.86 | ESR1 (0.72) | ALOX5VCPMAPTSMN1; SMN2TDP1 | |
| SCHEMBL7112167 | 0.86 | ALOX5 (0.75) | ALOX5VCPMAPTSMN1; SMN2TDP1 | |
| SCHEMBL6926815 | 0.85 | ALOX5 (0.85) | ALOX5VCPMAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | claimed |
| US-6586453-B2 | Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | claimed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6586453-B2 | Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | ALOX5 3410/4885VCP 1270/4885MAPT 2207/4885 |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | ALOX5 2040/4885VCP 2778/4885MAPT 2307/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | ALOX5 3410/4885VCP 1270/4885MAPT 2207/4885 |
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | ALOX5 2040/4885VCP 2778/4885MAPT 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.